![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
M.D. Anderson Cancer Center |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00477100 |
Primary Objective:
To prospectively collect tissue, serum, plasma, clinical, and imaging data from patients with recently diagnosed inflammatory breast cancer (IBC).
Condition | Intervention |
---|---|
Breast Cancer |
Other: Interview Procedure: Blood and Tissue Collection |
Study Type: | Observational |
Study Design: | Case Control, Prospective |
Official Title: | Inflammatory Breast Cancer (IBC) Registry |
The collection of serum and plasma from patients with inflammatory breast cancer.
Estimated Enrollment: | 200 |
Study Start Date: | April 2007 |
Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
1
Patients with recently diagnosed with inflammatory breast cancer (IBC) and have not received any treatment at this time.
|
Other: Interview
Interview
Procedure: Blood and Tissue Collection
For this study, additional blood (about 4 tablespoons)collected during a routine blood draw, additional breast tissue collected at the time of standard diagnostic procedure, and a core and a skin biopsy collected at the time of standard diagnostic procedure.
|
IBC:
IBC is a rare but rapidly growing form of breast cancer. Currently, there are no known risk factors and biological features (such as in the genes) that researchers can use to help design better treatments for IBC.
Study Participation
Participants in this study will be identified at the time of their first visit to M. D. Anderson. If you agree to take part in this study, you will have the following tests/procedures performed:
Length of Study:
Your participation in this study will be complete after your samples and data are collected.
Research Tissue Bank:
Before your blood and tissue samples and information can be used for research, the people doing the research must get specific approval from the Institutional Review Board (IRB) of M. D. Anderson. The IRB is a committee made up of doctors, researchers, and members of the community. The IRB is responsible for protecting the participants involved in research studies and making sure all research is done in a safe and ethical manner. All research done at M. D. Anderson, including research involving your samples and information from this bank, must first be approved by the IRB.
This is an investigational study. Up to 200 patients will take part in this study. Up to 150 will be enrolled at M.D. Anderson.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Patients with recently diagnosed inflammatory breast cancer (IBC).
Inclusion:
Exclusion:
1. Secondary IBC
Contact: Massimo Cristofanilli, MD | 713-792-2360 |
United States, New Mexico | |
University of New Mexico | Recruiting |
Albuquerque, New Mexico, United States, 87131 | |
Contact: Melanie Royce, MD, PhD | |
United States, Texas | |
U.T.M.D. Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
Principal Investigator: Massimo Cristofanilli, MD |
Principal Investigator: | Massimo Cristofanilli, MD | U.T.M.D. Anderson Cancer Center |
Responsible Party: | U.T. M.D. Anderson Cancer Center ( Massimo Cristofanilli, MD/Assoc. Professor ) |
Study ID Numbers: | 2006-1072 |
Study First Received: | May 18, 2007 |
Last Updated: | September 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00477100 |
Health Authority: | United States: Institutional Review Board |
Inflammatory Breast Cancer Cancer Registry Core Biopsy Skin Biopsy IBC |
Inflammatory breast cancer Skin Diseases Breast Neoplasms Breast Diseases |
Neoplasms Neoplasms by Site |